Literature DB >> 23585604

Chronic inflammatory demyelinating polyradiculoneuropathy: in a remote northern Ontario hospital.

Taryn Taylor1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23585604      PMCID： PMC3625082     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  11 in total

1.  Age of onset influences clinical features of chronic inflammatory demyelinating polyneuropathy.

Authors:  N Hattori; K Misu; H Koike; M Ichimura; M Nagamatsu; M Hirayama; G Sobue
Journal:  J Neurol Sci       Date:  2001-02-15       Impact factor: 3.181

2.  Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England.

Authors:  M P Lunn; H Manji; P P Choudhary; R A Hughes; P K Thomas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-05       Impact factor: 10.154

Review 3.  The pathogenesis of CIDP: rationale for treatment with immunomodulatory agents.

Authors:  Klaus V Toyka; Ralf Gold
Journal:  Neurology       Date:  2003-04-01       Impact factor: 9.910

4.  European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision.

Authors:  P Y K Van den Bergh; R D M Hadden; P Bouche; D R Cornblath; A Hahn; I Illa; C L Koski; J-M Léger; E Nobile-Orazio; J Pollard; C Sommer; P A van Doorn; I N van Schaik
Journal:  Eur J Neurol       Date:  2010-03       Impact factor: 6.089

Review 5.  Chronic inflammatory demyelinating polyneuropathy--update on pathogenesis, diagnostic criteria and therapy.

Authors:  Hubertus Köller; Michael Schroeter; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Curr Opin Neurol       Date:  2005-06       Impact factor: 5.710

6.  European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society.

Authors:  R A C Hughes; P Bouche; D R Cornblath; E Evers; R D M Hadden; A Hahn; I Illa; C L Koski; J M Léger; E Nobile-Orazio; J Pollard; C Sommer; P Van den Bergh; P A van Doorn; I N van Schaik
Journal:  Eur J Neurol       Date:  2006-04       Impact factor: 6.089

Review 7.  Chronic inflammatory demyelinating polyneuropathies: current treatment strategies.

Authors:  Thomas B Toothaker; Thomas H Brannagan
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

8.  Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P P Choudhary; N Thompson; R A Hughes
Journal:  J Neurol       Date:  1995-03       Impact factor: 4.849

9.  A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P J Dyck; W J Litchy; K M Kratz; G A Suarez; P A Low; A A Pineda; A J Windebank; J L Karnes; P C O'Brien
Journal:  Ann Neurol       Date:  1994-12       Impact factor: 10.422

10.  Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin.

Authors:  P P Choudhary; R A Hughes
Journal:  QJM       Date:  1995-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.